Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis

  Free Subscription


Articles published in Am J Gastroenterol

Retrieve available abstracts of 73 articles:
HTML format



Single Articles


    March 2024
  1. HIRODE G, Hansen BE, Chen CH, Su TH, et al
    Limited sustained remission after nucleos(t)ide analogue withdrawal: Results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study).
    Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002759.
    PubMed     Abstract available


  2. HIRODE G, Hansen BE, Chen CH, Su TH, et al
    Erratum: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).
    Am J Gastroenterol. 2024 Mar 8. doi: 10.14309/ajg.0000000000002718.
    PubMed    


    February 2024
  3. BUI H, Kumar NG, Singal AG, Boparai J, et al
    Implementation of a hepatocellular carcinoma surveillance program in a community-based integrated health system in patients with hepatitis C cirrhosis.
    Am J Gastroenterol. 2024 Feb 9. doi: 10.14309/ajg.0000000000002704.
    PubMed     Abstract available


  4. HSU CE, Liaw YF
    Hepatitis B Surface Antigen Kinetics After Tenofovir Withdrawal in Chronic Hepatitis B.
    Am J Gastroenterol. 2024;119:389-390.
    PubMed    


    January 2024
  5. JOPHLIN LL, Singal AK, Bataller R, Wong RJ, et al
    ACG Clinical Guideline: Alcohol-Associated Liver Disease.
    Am J Gastroenterol. 2024;119:30-54.
    PubMed     Abstract available


    December 2023
  6. HU TH, Luh DL, Tsao YY, Lin TY, et al
    Utilizing the Diabetes Care System for A County-wide Hepatitis C Elimination: An Integrated Community-based Shared Care Model in Taiwan.
    Am J Gastroenterol. 2023 Dec 12. doi: 10.14309/ajg.0000000000002624.
    PubMed     Abstract available


  7. BARRITT AS 4TH, Barnhart H, Gu J, Dellinger A, et al
    When Is Suspected Drug-Induced Liver Injury (DILI) Not DILI? An Analysis of Unlikely Cases From the Drug-Induced Liver Injury Network.
    Am J Gastroenterol. 2023;118:2301-2304.
    PubMed     Abstract available


    September 2023
  8. LIAW YF
    Impact of ALT Changes on the Risk of HCC in Hepatitis B-Compensated Cirrhotic Patients With Low Viremia.
    Am J Gastroenterol. 2023;118:1701.
    PubMed    


  9. PAINE ER
    Continuing Medical Education Questions: September 2023.
    Am J Gastroenterol. 2023;118:1544.
    PubMed     Abstract available


    August 2023
  10. CHAN HLY, Buti M, Lim YS, Agarwal K, et al
    Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
    Am J Gastroenterol. 2023 Aug 10. doi: 10.14309/ajg.0000000000002468.
    PubMed     Abstract available


  11. KIM DY, Kim YR, Suh C, Yoon DH, et al
    A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Am J Gastroenterol. 2023;118:1373-1380.
    PubMed     Abstract available


    July 2023
  12. BARNHILL MS, Vargas HE
    Immune-Checkpoint Inhibitors in the Hepatitis C-Infected Patient: To Use or Not to Use?
    Am J Gastroenterol. 2023 Jul 10. doi: 10.14309/ajg.0000000000002352.
    PubMed    


    June 2023
  13. PERRILLO R, Lok AS, Leonard K, Ghany MG, et al
    Association of ALT Flares to Hepatitis B Surface Decline During Tenofovir Alone or with Pegylated Interferon Alfa.
    Am J Gastroenterol. 2023 Jun 13. doi: 10.14309/ajg.0000000000002355.
    PubMed     Abstract available


  14. COUKOS A, Uldry E, Meylan S, Schmidt S, et al
    An Unusual Cause of Severe Granulomatous Hepatitis and Jaundice.
    Am J Gastroenterol. 2023 Jun 13. doi: 10.14309/ajg.0000000000002358.
    PubMed    


  15. LIM J, Kim YJ, Kim S, Choi J, et al
    Increased Risk of Osteoporotic Fracture in Patients with Autoimmune Hepatitis.
    Am J Gastroenterol. 2023 Jun 13. doi: 10.14309/ajg.0000000000002354.
    PubMed     Abstract available


  16. YIBIRIN M, Mustafayev K, Hosry J, Pundhir P, et al
    Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors.
    Am J Gastroenterol. 2023 Jun 13. doi: 10.14309/ajg.0000000000002361.
    PubMed     Abstract available


    April 2023
  17. MARCHEGIANI F, Laurent A, de'Angelis N
    Abdominal mass in a patient with autoimmune hepatitis, ulcerative colitis and BRCA family history - not always what you expect.
    Am J Gastroenterol. 2023 Apr 11. doi: 10.14309/ajg.0000000000002284.
    PubMed    


  18. VATSALYA V, Feng W, Kong M, Hu H, et al
    The Beneficial Effects of Lactobacillus GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis.
    Am J Gastroenterol. 2023 Apr 11. doi: 10.14309/ajg.0000000000002283.
    PubMed     Abstract available


    March 2023
  19. HASSANEIN T, McClain CJ, Vatsalya V, Stein LL, et al
    Safety, Pharmacokinetics, & Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-associated Hepatitis.
    Am J Gastroenterol. 2023 Mar 31. doi: 10.14309/ajg.0000000000002275.
    PubMed     Abstract available


  20. GHANY MG, Saraswat VA
    Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat?
    Am J Gastroenterol. 2023 Mar 20. doi: 10.14309/ajg.0000000000002224.
    PubMed     Abstract available


  21. HUR MH, Park MK, Cheuk-Fung Yip T, Chen CH, et al
    Personalized Antiviral Drug Selection in Chronic Hepatitis B Patients Using a Machine Learning Model: A Multinational Study.
    Am J Gastroenterol. 2023 Mar 7. doi: 10.14309/ajg.0000000000002234.
    PubMed     Abstract available


    January 2023
  22. MARTIN P, Jacobson IM
    New Therapies and Management Options for Hepatitis D.
    Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002153.
    PubMed    


  23. HIRODE ASG, Hansen BE, Chen CH, Su TH, et al
    Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: Results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study).
    Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002203.
    PubMed     Abstract available


  24. FELD JJ, Wahed AS, Fried M, Ghany MG, et al
    Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial.
    Am J Gastroenterol. 2023 Jan 13. doi: 10.14309/ajg.0000000000002176.
    PubMed     Abstract available


  25. YANG J, Choi WM, Shim JH, Lee D, et al
    Low level of hepatitis B viremia compared with undetectable viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis.
    Am J Gastroenterol. 2023 Jan 9. doi: 10.14309/ajg.0000000000002181.
    PubMed     Abstract available


  26. TERRAULT NA, Lok AS, Wahed AS, Ghany MG, et al
    Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
    Am J Gastroenterol. 2023 Jan 5. doi: 10.14309/ajg.0000000000002125.
    PubMed     Abstract available


  27. JUNG J, Nguyen MH
    Liver-Related Mortality in Hepatitis B Virus Core Antibody+/Hepatitis B Virus Surface Antigen- Patients: Occult Hepatitis B Virus, Hepatitis B Virus Reactivation, and Hepatocellular Carcinoma Development.
    Am J Gastroenterol. 2023;118:24-25.
    PubMed     Abstract available


    December 2022
  28. BUSHYHEAD DW
    Continuing Medical Education Questions: December 2022.
    Am J Gastroenterol. 2022;117:1909.
    PubMed     Abstract available


    November 2022
  29. KRAMER JR, Cao Y, Li L, Smith D, et al
    Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection.
    Am J Gastroenterol. 2022;117:1834-1844.
    PubMed     Abstract available


  30. SHOREIBAH M
    Continuing Medical Education Questions: November 2022.
    Am J Gastroenterol. 2022;117:1742.
    PubMed     Abstract available


    October 2022
  31. YUN B, Oh J, Ahn SH, Yoon JH, et al
    Comparable mortality between Asian chronic hepatitis B patients under long-term antiviral therapy vs. matched control: a population-based study.
    Am J Gastroenterol. 2022 Oct 25. pii: 00000434-990000000-00555.
    PubMed     Abstract available


    September 2022
  32. VELOZ MFG, Han K, Oakes K, Robertson D, et al
    Results of a model of delivering hepatitis C care in a homeless metropolitan population in England.
    Am J Gastroenterol. 2022 Sep 30. pii: 00000434-990000000-00534.
    PubMed     Abstract available


  33. SOHN W, Chang Y, Cho YK, Hong YS, et al
    Isolated Hepatitis B core antibody positivity and long-term liver-related mortality in Korea: A cohort study.
    Am J Gastroenterol. 2022 Sep 6. pii: 00000434-990000000-00499.
    PubMed     Abstract available


  34. WU S, Zhou J, Wu X, Sun Y, et al
    Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.
    Am J Gastroenterol. 2022;117:1444-1453.
    PubMed     Abstract available


    August 2022
  35. SINGH SP, Jindal A, Sharma MK, Sarin SK, et al
    Much more is needed from Hepatitis B Core-related antigen to predict Risk of Liver cancer.
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00453.
    PubMed    


  36. WONG RJ, Kaufman HW, Niles JK, Chen C, et al
    Low Performance of Hepatitis Delta Virus Testing Among Two National Cohorts of Chronic Hepatitis B Patients in the United States.
    Am J Gastroenterol. 2022 Aug 12. pii: 00000434-990000000-00461.
    PubMed     Abstract available


  37. LIM N, Kwong AJ, Jafri SM, Jesse MT, et al
    Heterogeneity in Center Practices in Liver Transplantation for Alcohol-associated Liver Disease in the United States.
    Am J Gastroenterol. 2022 Aug 1. pii: 00000434-990000000-00443.
    PubMed     Abstract available


    July 2022
  38. WEINBERG EM, Dukewich M, Jakhete N, Stonesifer E, et al
    Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation.
    Am J Gastroenterol. 2022 Jul 11. pii: 00000434-990000000-00432.
    PubMed     Abstract available


  39. GONZALEZ SA, Kamath PS
    Lung Infection in Severe Alcohol-related Hepatitis: Not to be Underestimated.
    Am J Gastroenterol. 2022;117:1044-1045.
    PubMed    


    June 2022
  40. INNES H, Hamill V, McDonald SA, Hayes PC, et al
    Comparing predicted probability of hepatocellular carcinoma in cirrhosis patients to the general population: an opportunity to improve risk communication?
    Am J Gastroenterol. 2022 Jun 24. pii: 00000434-990000000-00428.
    PubMed     Abstract available


  41. GENG CX, Gudur A, Patterson D, Stotts MJ, et al
    Concordance of ICD-10 Codes and the Clinical Diagnosis of Alcoholic Hepatitis.
    Am J Gastroenterol. 2022 Jun 17. pii: 00000434-990000000-00420.
    PubMed     Abstract available


  42. CALVARUSO V, Celsam C, D'Ambrosio R, Simone F, et al
    RESIST-HCV criteria to monitor progression of low-risk esophageal varices in patients with compensated cirrhosis after HCV eradication. The SIMPLE study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
    Am J Gastroenterol. 2022 Jun 17. pii: 00000434-990000000-00413.
    PubMed     Abstract available


  43. FONTANA RJ, Engle RE, Hayashi PH, Gu J, et al
    The Incidence of Hepatitis E infection in American Patients with Suspected Drug-Induced Liver Injury is low and declining: The DILIN Prospective Study.
    Am J Gastroenterol. 2022 Jun 10. pii: 00000434-990000000-00401.
    PubMed     Abstract available


    May 2022
  44. AMPUERO J, Carmona I, Sousa F, Rosales JM, et al
    Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure.
    Am J Gastroenterol. 2022;117:819.
    PubMed    


  45. MORALES-ARRAEZ D, Ventura-Cots M, Altamirano J, Abraldes JG, et al
    Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.
    Am J Gastroenterol. 2022;117:818.
    PubMed    


    March 2022
  46. NTANDJA WANDJI LC, Ningarhari M, Lemaitre E, Khaldi M, et al
    Lung infection impacts access to treatment and short-term outcome in patients with severe alcohol-related hepatitis treated with corticosteroids.
    Am J Gastroenterol. 2022 Mar 28. pii: 00000434-990000000-00311.
    PubMed     Abstract available


  47. YUN B, Ahn SH, Yoon JH, Kim BK, et al
    Clinical indication of aspirin associated with reduced risk of liver cancer in chronic hepatitis B: A nationwide cohort study.
    Am J Gastroenterol. 2022 Mar 14. pii: 00000434-990000000-00276.
    PubMed     Abstract available


    February 2022
  48. TSENG TC, Hosaka T, Liu CJ, Suzuki F, et al
    Hepatitis B Core-related Antigen Stratifies the Risk of Liver Cancer in HBeAg-negative Patients with Indeterminate Phase.
    Am J Gastroenterol. 2022 Feb 16. pii: 00000434-990000000-00267.
    PubMed     Abstract available


  49. JENA A, Choudhury A, Singh AK
    MELD vs Maddrey Discriminant Function in Alcoholic Hepatitis: The Battle for the Best Score.
    Am J Gastroenterol. 2022 Feb 10. pii: 00000434-990000000-00248.
    PubMed    


  50. CHANG R, Chen HY, Wei JC
    Increased Cancer Risk in Autoimmune Hepatitis: A Danish Nationwide Cohort Study.
    Am J Gastroenterol. 2022 Feb 8. pii: 00000434-990000000-00243.
    PubMed    


  51. LI J, Henry L, Nguyen MH
    Chronic hepatitis B and fatty liver -weal or woe?
    Am J Gastroenterol. 2022 Feb 2. pii: 00000434-990000000-00238.
    PubMed    


    January 2022
  52. FAYED A, Hegazy MT, Biard L, Vieira M, et al
    Relapse of HCV-Cryoglobulinemic Vasculitis Following Sustained Viral Response after Interferon-free Direct-Acting Antivirals.
    Am J Gastroenterol. 2022 Jan 29. pii: 00000434-990000000-00234.
    PubMed     Abstract available


    December 2021
  53. MORALES-ARRAEZ D, Ventura-Cots M, Altamirano J, Abraldes JG, et al
    The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.
    Am J Gastroenterol. 2021 Dec 28. pii: 00000434-990000000-00179.
    PubMed     Abstract available


  54. CACOUB P, Asselah T
    Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease.
    Am J Gastroenterol. 2021 Dec 16. pii: 00000434-990000000-00166.
    PubMed     Abstract available


    October 2021
  55. JENSEN MD, Jepsen P, Vilstrup H, Gronbaek L, et al
    Increased Cancer Risk in Autoimmune Hepatitis: A Danish Nationwide Cohort Study.
    Am J Gastroenterol. 2021 Oct 8. pii: 00000434-990000000-00120.
    PubMed     Abstract available


  56. LI J, Le MH, Barakat MT, Cheung RC, et al
    The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016.
    Am J Gastroenterol. 2021;116:2068-2078.
    PubMed     Abstract available


    September 2021
  57. LEE HW, Park SY, Lee YR, Lee H, et al
    Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL.
    Am J Gastroenterol. 2021 Sep 10. pii: 00000434-990000000-00096.
    PubMed     Abstract available


  58. AMPUERO J, Carmona I, Sousa F, Rosales JM, et al
    A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure.
    Am J Gastroenterol. 2021 Sep 9. pii: 00000434-900000000-98663.
    PubMed     Abstract available


  59. CHUANG WL, Hu TH, Buggisch P, Moreno C, et al
    Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
    Am J Gastroenterol. 2021;116:1924-1928.
    PubMed     Abstract available


  60. ZAMOR PJ, Brown A, Dylla DE, Dillon JF, et al
    High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
    Am J Gastroenterol. 2021;116:1896-1904.
    PubMed     Abstract available


    August 2021
  61. KONSTANTELOS N, Shakeri A, McCormack D, Feld JJ, et al
    Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada.
    Am J Gastroenterol. 2021;116:1738-1740.
    PubMed     Abstract available


    June 2021
  62. SCHAEFER EAK
    A Deep Ravine Rather Than a Shallow Gap: Many More Bridges Needed to Improve Care of Chronic Hepatitis B in the United States.
    Am J Gastroenterol. 2021 Jun 30. pii: 00000434-990000000-00023.
    PubMed     Abstract available


  63. YU X
    Pay Attention to Distinguish Hepatitis from Novel Coronavirus Hepatitis in the Context of COVID-19 Pandemic.
    Am J Gastroenterol. 2021;116:1354-1355.
    PubMed    


  64. RINALDI L, Messina V, Di Marco V, Iovinella V, et al
    Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.
    Am J Gastroenterol. 2021;116:1248-1255.
    PubMed     Abstract available


  65. NGUYEN MH, Atsukawa M, Ishikawa T, Yasuda S, et al
    Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
    Am J Gastroenterol. 2021;116:1264-1273.
    PubMed     Abstract available


    April 2021
  66. TRAN S, Jeong D, Henry L, Cheung RC, et al
    Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study.
    Am J Gastroenterol. 2021 Apr 29. pii: 00000434-900000000-98796.
    PubMed     Abstract available


  67. SHARMA S, Saraya A
    Avoiding Beta Blockers in Patients of Hepatitis C Virus-Related Compensated Cirrhosis With Clinically Significant Portal Hypertension After Cure With Antivirals: Are We There Yet?
    Am J Gastroenterol. 2021 Apr 9. pii: 00000434-900000000-98829.
    PubMed    


  68. JI D, Chen Y, Shang Q, Liu H, et al
    Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.
    Am J Gastroenterol. 2021 Apr 8. pii: 00000434-900000000-98824.
    PubMed     Abstract available


  69. KHALILI M, Kleiner DE, King WC, Sterling RK, et al
    Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B.
    Am J Gastroenterol. 2021 Apr 8. pii: 00000434-900000000-98823.
    PubMed     Abstract available


  70. EISA M, Kennedy R, Teferra R, Heckroth M, et al
    SARS-COV-2 Infection in Patients With Alcohol-Associated Hepatitis: Metabolic Similarities and Treatment Challenges.
    Am J Gastroenterol. 2021;116:847-848.
    PubMed    


    March 2021
  71. ROGAL S, Youk A, Agbalajobi O, Zhang H, et al
    Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
    Am J Gastroenterol. 2021 Mar 30. pii: 00000434-900000000-98834.
    PubMed     Abstract available


  72. WONG RJ, Jain MK, Therapondos G, Niu B, et al
    Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
    Am J Gastroenterol. 2021 Mar 1. pii: 00000434-900000000-98873.
    PubMed     Abstract available


    February 2021
  73. TAN HK, Teng MLP, Soh AYS, Cheo SHY, et al
    Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites.
    Am J Gastroenterol. 2021 Feb 1. doi: 10.14309/ajg.0000000000001176.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.